Brokerages forecast that Epizyme Inc (NASDAQ:EPZM) will post ($0.56) earnings per share for the current quarter, Zacks reports. Five analysts have issued estimates for Epizyme’s earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.63). Epizyme posted earnings of ($0.53) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 5.7%. The company is scheduled to issue its next quarterly earnings report on Friday, August 14th.
On average, analysts expect that Epizyme will report full-year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($2.92) to ($2.09). For the next year, analysts forecast that the company will post earnings of ($2.09) per share, with EPS estimates ranging from ($2.76) to ($1.65). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Epizyme.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, May 4th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.23. The business had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.63 million. Epizyme had a negative return on equity of 67.19% and a negative net margin of 1,111.58%.
In other news, insider Matthew Ros sold 112,003 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $21.24, for a total value of $2,378,943.72. Following the transaction, the insider now owns 92,861 shares of the company’s stock, valued at $1,972,367.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David M. Mott bought 62,019 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was bought at an average cost of $16.03 per share, for a total transaction of $994,164.57. Following the acquisition, the director now owns 82,601 shares of the company’s stock, valued at approximately $1,324,094.03. The disclosure for this purchase can be found here. Insiders own 16.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its stake in shares of Epizyme by 53.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,706 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 592 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Epizyme by 20.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,678 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 1,114 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Epizyme by 8.9% in the fourth quarter. Amalgamated Bank now owns 14,320 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 1,174 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Epizyme by 7.1% in the fourth quarter. Virtus ETF Advisers LLC now owns 23,272 shares of the biopharmaceutical company’s stock valued at $572,000 after buying an additional 1,552 shares in the last quarter. Finally, Swiss National Bank boosted its stake in shares of Epizyme by 1.3% in the first quarter. Swiss National Bank now owns 141,300 shares of the biopharmaceutical company’s stock valued at $2,192,000 after buying an additional 1,800 shares in the last quarter. 90.43% of the stock is currently owned by institutional investors and hedge funds.
Epizyme stock traded up $0.76 during midday trading on Monday, reaching $16.27. 96,172 shares of the stock traded hands, compared to its average volume of 1,823,567. The company has a 50-day simple moving average of $17.99 and a two-hundred day simple moving average of $19.70. Epizyme has a 12-month low of $9.73 and a 12-month high of $27.82. The firm has a market cap of $1.57 billion, a PE ratio of -8.06 and a beta of 2.05. The company has a current ratio of 14.81, a quick ratio of 14.74 and a debt-to-equity ratio of 0.22.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Story: What is the CAC 40 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.